Copyright
©The Author(s) 2023.
World J Clin Cases. Mar 6, 2023; 11(7): 1607-1614
Published online Mar 6, 2023. doi: 10.12998/wjcc.v11.i7.1607
Published online Mar 6, 2023. doi: 10.12998/wjcc.v11.i7.1607
Number | Treatment | Dose of radiation | Response | Outcome | Ref. |
61 | Surgery (21), Surgery + chemotherapy (16), Surgery + radiation (3), Surgery + chemotherapy + radiation (2), Chemotherapy (16), Observation (3) | Not reported | Not reported | 5-year OS 93.6% | Cordier et al[5] |
19 | Chemotherapy (14), Surgery (2), Surgery + chemotherapy (2), Chemotherapy + radiation (1) | Not reported | 79% CR, 21% PR | Not reported | Zinzani et al[17] |
41 | Observation (5), Surgery (17), Chemotherapy (12), Surgery + chemotherapy (3), Surgery + radiation (1), Prednisone (2), Unknown (1) | Not reported | Not reported | Lymphoma-specificsurvival was 71.7% at 10 years | Kurtin et al[18] |
22 | Observation (2), Chemotherapy alone (2), Rituximab alone (2), Systemic chemotherapy ± Rituximab (12), Chemotherapy with rituximab (8), Surgery (6), Radiotherapy (2) | Not reported | --, 2 PR, 2 PR, 2 CR, 9 PR, 1 SD, 2 CR, 5 PR, 1 SD, 6 CR, 1 CR, 1 PR | 53 mo median PFS | Ahmed et al[19] |
18 | Observation (1), Surgery (6), Surgery + chemotherapy (8), Surgery + radiotherapy (1), Surgery + chemotherapy + radiotherapy (2) | Not reported | Not reported | 6 years median time to disease recurrence or death | Graham et al[20] |
61 | Surgery alone (17), Surgery + Chemotherapy (3), Surgery + Radiotherapy (2), Chemotherapy (28), Radiotherapy (6), Observation (5) | Not reported | 15 CR, 2 PR, 3 CR, 2 CR, 7 CR, 12 PR, 5 SD, 2 PD, 2 not valuable, 3 CR, 2 PR, 1 SD, 5 not valuable | median time to progression was 5.6 years. 5-year OS 89.7% | Oh et al[21] |
10 | Radiotherapy ± surgery ± chemotherapy ± rituximab | 2 Gy × 2 | 6 CR, 4 PR | 87.5% 5-year progression-free survival rate | Girinsky et al[15] |
1 | Radiotherapy (1) | 30 Gy | CR | No signs of recurrence are found 4 years after radiotherapy | Hashemi et al[13] |
2 | Radiotherapy + rituximab (1), Observation (1) | 50 Gy | CR, -- | Not reported | Kawaguchi et al[14] |
1 | Radiotherapy (1) | 30.6 Gy | CR | Survive more than 3.5 years | Our case |
- Citation: Zhen CJ, Zhang P, Bai WW, Song YZ, Liang JL, Qiao XY, Zhou ZG. Mucosa-associated lymphoid tissue lymphoma of the trachea treated with radiotherapy: A case report. World J Clin Cases 2023; 11(7): 1607-1614
- URL: https://www.wjgnet.com/2307-8960/full/v11/i7/1607.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i7.1607